Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 5,476 shares of the company’s stock after buying an additional 41 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Medpace were worth $1,828,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Schulhoff & Co. Inc. boosted its holdings in shares of Medpace by 11.6% in the third quarter. Schulhoff & Co. Inc. now owns 2,600 shares of the company’s stock valued at $868,000 after acquiring an additional 270 shares in the last quarter. Zions Bancorporation N.A. boosted its holdings in shares of Medpace by 18.4% during the third quarter. Zions Bancorporation N.A. now owns 7,118 shares of the company’s stock worth $2,376,000 after purchasing an additional 1,105 shares during the period. KBC Group NV grew its holdings in shares of Medpace by 5.5% during the 3rd quarter. KBC Group NV now owns 1,213 shares of the company’s stock valued at $405,000 after acquiring an additional 63 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of Medpace by 6.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after purchasing an additional 2,675 shares in the last quarter. Finally, Cumberland Partners Ltd raised its stake in shares of Medpace by 45.8% during the 3rd quarter. Cumberland Partners Ltd now owns 3,500 shares of the company’s stock worth $1,168,000 after purchasing an additional 1,100 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 7.5 %

Medpace stock opened at $334.84 on Friday. The stock has a market cap of $10.41 billion, a P/E ratio of 29.32, a P/E/G ratio of 2.00 and a beta of 1.37. The company’s 50 day moving average price is $342.27 and its two-hundred day moving average price is $376.61. Medpace Holdings, Inc. has a 52 week low of $268.80 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same period in the previous year, the business earned $2.22 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MEDP shares. Robert W. Baird downgraded Medpace from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $413.00 to $349.00 in a research note on Wednesday, October 23rd. Deutsche Bank Aktiengesellschaft decreased their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a report on Wednesday, July 24th. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, UBS Group cut Medpace from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $380.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.